What one share of Quantum Genesis AI holds
Quantumzyme Corp., is a biotransformation company, focused on clean and green chemistry. Specifically, Quantumzyme is in the business of developing engineered enzymes in the application of active pharmaceutical ingredients (“API”) production.
Quantum Genesis AI’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-04-30; the balance sheet is as of 2026-04-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.12 |
| Cash and investments | $0.00 |
| Debt | $0.01 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.03 | −$0.00 | — | — | — | $0.00 |
| 2018 | $0.02 | −$0.01 | $0.00 | −$0.00 | — | −$0.00 |
| 2024 | $0.00 | −$0.01 | — | — | — | −$0.01 |
| 2025 | $0.00 | −$0.01 | — | — | — | −$0.01 |
Common questions about Quantum Genesis AI
How much does one share of Quantum Genesis AI earn?
Over the last 12 months, Quantum Genesis AI lost $0.12 for each share.
Does Quantum Genesis AI pay a dividend?
Quantum Genesis AI didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Quantum Genesis AI’s book value per share?
Quantum Genesis AI’s book value is negative (−$0.01 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of April 30, 2026.
How much cash and debt does each share of Quantum Genesis AI have?
Each share of Quantum Genesis AI has $0.00 of cash and investments and $0.01 of debt, as of April 30, 2026.
Has Quantum Genesis AI bought back shares?
Quantum Genesis AI’s share count rose about 778% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.